Dapagliflozin for heart rhythm problems in diabetes
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial studies dapagliflozin, a diabetes medicine, to see if it can help people with paroxysmal atrial fibrillation (irregular heart rhythm). If you have both diabetes and this type of AF, the study may offer a chance to improve your heart rhythm and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diabetes (DM) that has been diagnosed
- You have paroxysmal atrial fibrillation (episodes that come and go)
- You do not have type 1 diabetes
- Your blood pressure is not too low (systolic is 90 or higher)
- Your kidneys are working fairly well (eGFR 30 or higher)
- You are not currently taking dapagliflozin or other SGLT2 inhibitors
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.
This trial tests whether an SGLT2 inhibitor pill can help people who have atrial fibrillation (an irregular heartbeat) and type 2 diabetes. You may be eligible if you’re in the right age range, on diabetes pills only, and meet specific heart and lab criteria.
This trial tests if enavogliflozin, a diabetes drug, can help prevent atrial fibrillation (an irregular heartbeat) from coming back after a catheter ablation procedure in people with heart failure. If you've recently had or are planning this procedure, this study may offer a new way to keep your heart rhythm steady.
This study tests whether a medicine called dapagliflozin (usually used for diabetes) can reduce heart tissue changes in people with persistent atrial fibrillation. It is given along with the standard ablation procedure, aiming to improve the heart's electrical health and potentially make the procedure more effective.
This trial tests if the diabetes drug dapagliflozin can lower the chance of atrial fibrillation (an irregular heartbeat) coming back after a procedure called electrical cardioversion, which uses a shock to restore a normal heart rhythm. If you have AF and are scheduled for cardioversion, you may be able to join.
This trial tests if the medicine dapagliflozin (commonly used for diabetes and heart failure) can help prevent atrial fibrillation from coming back after a catheter ablation. By taking this medicine after your first ablation, researchers hope to reduce the chance of the irregular heartbeat returning.
Hear when a new Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.